Drug-associated facial dyskinesias - a study of 238 patients

Journal of Neuro-Ophthalmology

Volumn 18, Issue 2, 1998, Pages 153-157

  Mauriello, Joseph A ^a   Carbonaro, Paul ^a   Dhillon, Shamina ^a   Leone, Tina ^a   Franklin, Mark ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Blepharospasm; Botulinum toxin A; Drugs; Facial dyskinesias; Meige syndrome

Indexed keywords

EID: 84997144479     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/00041327-199806000-00016     Document Type: Article

References (24)

1. Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann Intern Med 1981;94: 788-93.
2. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacologic findings in 100 patients. Ann Neurol 1983;13: 402-11.
3. Brait KA, Zagerman AJ. Dyskinesias after antihistamine use. N Engl J Ophthalmol 1977;296: 111.
4. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32: 1335-46.
5. Thach BT, Chase TN, Bosnia JF. Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Ophthalmol 1977;293: 486-7.
6. Casey DE. Tardive dyskinesia: reversible and irreversible. Psy-chophannacology Suppl 1985;2: 88-97.
7. DeVeaugh-Geiss J. Clinical changes in tardive dyskinesia during long-term follow-up. In: Wolf ME, Mosnia AD, eds. Tardive dyskinesia: biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press, 1988: 89-105.
8. Klawans H, Tanner GM, Barr A. The reversibility of “permanent”tardive dyskinesia. Clin Neuropharmacol 1984;7: 153-9.
9. Wojcik JD, Falk WE, Fink SJ, Cole JO, Gelenberg AJ. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991;148: 1055-9.
10. Powers JM. Decongestanl-induced blepharospasm and orofacial dystonia. JAMA 1982;247: 3244-5.
11. Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. In: Jankovic J, Tolosa E, eds. Advances in neurology. New York: Raven Press, 1988: 103-16. (Vol 49;Facial dyskinesias).
12. Tolosa E, Kuliscvsky J. Dopaminergic mechanisms in cranial dystonia. In: Jankovic J, Tolosa E, eds. Advances in neurology. New York: Raven Press, 1988: 433-41. (Vol 49: Facial dyskinesias).
13. Task Force on Late Neurological Effects of Antipsychotic Drugs. Tardive dyskinesia: summary of a task force report on the American Psychiatric Association. Am J Psychiatry 1980: 137;1163-72.
14. Dekret J, Maany I, Ramsey TA, et al. A case of oral dyskinesia associated with imipramine treatment. Am J Psychiatry 1977;134: 1297-8.
15. Scott AN, Kennedy RA, Stubbs HA. Botulinum A toxin injections as a treatment for blepharospasm. Arch Ophthalmol 1985;103: 347-50.
16. Frueh BR, Musch DC. Treatment of facial spasm with botulinum toxin: an interim report. Ophthalmology 1986;93: 917-23.
17. Kraft SP, Long AE. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid lascictilalions. Can J Neurol Sei 1988;15: 276-80.
18. Cohen DA, Savino PJ, Stern MB, et al. Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin Neuropharmacol 1986;9: 415-29.
19. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol 1987;71: 664-8.
20. Dutton JJ, Buckley EG. Long-term results and complications of Botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988;95: 1529-34.
21. Mauriello JA, Aljian J. The natural history of treatment of facial dyskinesias with botulinum toxin: a study of fifty consecutive patients over seven years. Br J Ophthalmol 1992;76: 349-52.
22. Mauriello JA. Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 1985;35: 1499-500.
23. Schreiber S, Pick CG. Fluoxetine for blepharospasm: interaction of serotonin and dopamine. J Nerv Meat Dis 1995;183: 719-21.
24. Lauterbach ED, Price ST, Spears TE, Jackson JG, Kirsh AD. Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 1994;35: 488-90.